In the study, subjects will scheduled to undergo four 21-days cycles of chemotherapy
treatment. Three group were treated with MW05 300 g/kg or MW05 500 g/kg or PEG-rhG-CSF 100
g/kg on the 3th day of each cycle randomized 1:1:1 .
The dose of the experimental drug MW05 in phase III were determined by independent data
monitoring committee (IDMC) according to the efficacy and safety of phase II. Subjects were
randomly divided into two groups 1:1 to received either MW05 or PEG-rhG-CSF(100 g/kg) on the
3th day of each chemotherapy cycle.
Study Stage: Phase II/III Study Population Female patients with breast cancer will be
enrolled to receive at least 4 cycles of TC chemotherapy, that is: Docetaxel 75 mg/m2 and
Cyclophosphamide 600 mg/m2.
Study Design: A multi-center, randomized, open-label, active-controlled phase II/III clinical
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.